QUANTA-SYSTEM
31.1.2024 07:31:25 CET | Business Wire | Press release
Quanta System proudly opens the door to the New Year by unleashing the ultimate innovation in the picosecond laser technologies: Discovery PICO with VarioPulse Technology®. An unprecedented level of precision and versatility in a device that allows you to select the picosecond pulse-duration to personalize the treatments to meet the unique needs of each person.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240130556983/en/
Pico Filling Treatment - skin rejuvenation (Photo: Business Wire)
Quanta System has always been committed to follow the evolving needs of the market and to listen and understand the needs of its customers. Discovery PICO VarioPulse Technology® represents a significant leap forward in the world of aesthetic medicine.
Featuring Pico Boost technology that can deliver up to 1.8GW of laser power perfectly controlled by the VarioPulse Technology®, this next-generation device welcomes you to 3 cutting-edge customized treatments that are precisely designed to perform tattoo removal and skin revitalization at their best.
Pico Tune-Ink, the adaptable treatment that removes tattoo ink of a wide variety of colour and complexity;
Pico Filling, the no down-time treatment that revitalizes the skin from within and improve its appearance;
Pico Plasma, the all round skin remodeling treatment that targets scars and acne scars.
Commenting on this major launch, Girolamo Lionetti, CEO of Quanta System, expresses his excitement, "We are thrilled to bring this new technology to the aesthetic world. Our primary goal of improving people's quality of life is greatly enhanced by continuing to work alongside our valued partners, the physicians, and providing patients with more and more customized treatments.”
This is just the first step of a new era laser roadmap focused on delivering the superior user experience and patient satisfaction that the market has been waiting for.
For more information about Discovery PICO VarioPulse Technology®, visit our website www.quantasystem.com or come to discover it in person at IMCAS Booth U322 Level 3 - February 1st -3rd 2024.
About Quanta System
For almost forty years Quanta System, a 100% Italian company distributed worldwide, is the reference point for the research, designing and manufacture of state-of-the-art laser systems for surgery, dermatology and aesthetic medicine and the conservation of art works.
In 2004 the company joins El.En. SpA, leader on the laser market listed on the Euronext STAR Milan ("STAR") of the Italian Stock Exchange and a partner of reference for health facilities, Institutions and Entities engaged in scientific and research projects at a global level.
Designed to be used by doctors, specialised operators and restorers, today the Quanta System lasers represent the "Gold Standard" thanks to a wide range of applications.
The laser systems are entirely manufactured in Italy: from Research & Development to production, the entire process takes place in the company's headquarters in Samarate (in the province of Varese).
Quanta System is a trusted partner, day in day out, of all doctors in every part of the world thanks to its ability to listen, its straightforward debates and the creation of new systems that increasingly meet the real needs of professionals so they can provide better care for their patients.
A constantly evolving company that has managed to update its production so that it has always managed to satisfy the developing needs of its time, without losing sight of its primary objective: contributing to the improvement of people's quality of life.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240130556983/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom